Q-omics provides the consensus-scored PXDNL profile across patient tissues and cancer cell-line models. PXDNL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PXDNL is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, PXDNL RNA expression shows 17,858 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, LIHC, and UVM as cancer lineages where PXDNL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PXDNL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PXDNL survival associations across molecular data types. PXDNL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PXDNL RNA expression–survival associations across cancer types. High PXDNL expression shows unfavorable associations in BLCA, UVM, BRCA, LGG, CESC and COAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PXDNL RNA expression.
This table summarizes PXDNL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PXDNL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PXDNL shows lower tumor expression in KIRP, KICH and THCA and higher tumor expression in LIHC, HNSC and BLCA. The LIHC box plot shows higher PXDNL RNA expression in tumor versus normal tissue (log2 FC = +0.546, t-test p < 0.001).
This table shows molecular features associated with PXDNL in patient tissues and cancer cell lines. In patient samples, PXDNL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PXDNL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
